Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.34 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865996 | 0.98 | HRH3 (0.38) | TDP1HRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL6978047 | 0.84 | SIGMAR1 (0.39) | LTA4HPOLBHRH3HSD17B10 | |
| SCHEMBL6978377 | 0.82 | HDAC3 (0.46) | TDP1KDM4EPOLBHRH3CYP1A2 | |
| SCHEMBL9945525 | 0.80 | PSMB1 (0.38) | TDP1CARM1PRMT6PRMT8LTA4H | |
| SCHEMBL6979248 | 0.80 | HPGD (0.36) | — | |
| SCHEMBL9944287 | 0.79 | KDM4E (0.42) | TDP1LTA4HKDM4EPOLBHRH3 | |
| SCHEMBL9945422 | 0.79 | PSMB1 (0.40) | TDP1LTA4HKDM4EHRH3PSMB1 | |
| SCHEMBL6955961 | 0.79 | PSMB1 (0.38) | TDP1CARM1PRMT6PRMT8LTA4H | |
| SCHEMBL9944259 | 0.77 | PSMB1 (0.44) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL6976370 | 0.77 | DRD3 (0.48) | TDP1KDM4EHRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | TDP1 4067/4885CARM1 2808/4885PRMT6 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.